Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07776574

Deep Endometriosis Affecting the Urogenital Tract: Long-term Outcomes and Impact on Renal Function

Endometriosis is a chronic estrogen-dependent disease characterized by the presence and growth of endometrium-like tissue outside the uterine cavity.

This ectopic endometrial tissue induces a chronic local and systemic inflammatory response, resulting in the most common manifestations of the disease: chronic pelvic pain, infertility, and pelvic adhesions. In deep endometriosis (DE), adhesions and infiltrative growth may damage adjacent organs.

Overall, endometriosis affects approximately 10% of women of reproductive age. Its prevalence is higher among women with infertility (20-50%) and among patients with chronic pelvic pain (up to 90%).

The disease is usually categorized as superficial peritoneal, ovarian, or deep endometriosis (DE). Deep endometriosis is a progressive form of the disease that may affect organs beyond the pelvic cavity, including the urinary tract, alter their anatomy, and cause functional impairment.

Urogenital involvement occurs in approximately 1-5.5% of all women with endometriosis; the prevalence is substantially higher among patients with DE, reaching 16-53% according to the available literature.

Within the urinary tract, the bladder is most commonly affected (70-85%), followed by the ureters (9-23%), kidneys (approximately 4%), and urethra (approximately 2%).

Ureteral endometriosis is therefore a relatively rare but clinically significant entity. It may be unilateral or bilateral, with a predominance of left-sided involvement.

Two basic forms are distinguished:

* "Extrinsic" - ureteral stenosis caused by periureteral fibrosis and the presence of DE lesions without infiltration of the ureteral wall. * "Intrinsic" - ureteral stenosis caused by direct infiltration of the ureteral wall by endometriotic tissue.

Ureteral stenosis causes secondary hydronephrosis and, unless treated in a timely manner, may lead to a progressive loss of renal function.

The disease frequently remains asymptomatic for a prolonged period. Up to half of cases are diagnosed incidentally or only at an advanced stage, when renal damage is already irreversible.

Early detection and timely planning of surgical management are therefore essential for preserving renal function.

The main surgical procedures are:

* ureterolysis - release of the ureter from fibrotic adhesions, preferred for the extrinsic form; * ureteroneocystostomy (UCNA) - indicated for the intrinsic form when the affected segment must be resected and the ureter reimplanted into the bladder; * ureteroureterostomy (ureteral anastomosis) - appropriate for the intrinsic form when, following resection, the distal ureteral segment is sufficiently long to allow anastomosis of healthy margins.

Despite the clinical significance of the condition, prospective studies objectively evaluating the evolution of renal function after the individual types of surgical management of ureteral endometriosis are still lacking.

A modern diagnostic strategy combining specialized ultrasound, dynamic renal scintigraphy (MAG3), and analysis of urinary biomarkers of tubular injury (KIM-1, CCL-2, L-FABP) enables earlier detection of renal dysfunction and more accurate monitoring of postoperative recovery. Identification of sensitive biomarkers of early renal injury and validation of an algorithm for their use could substantially improve decisions regarding the timing of surgery and subsequent postoperative follow-up.

Based on our experience, some patients surgically treated for hydronephrosis caused by DE-related ureteral stenosis show persistent morphological changes on renal ultrasound and the manifestation of systemic conditions such as arterial hypertension during long-term follow-up. To date, no study has focused on the long-term follow-up of patients with ureteral DE and its potential consequences. The expected benefit of this study is to establish clear criteria for the indication of surgical treatment of ureteral endometriosis and to develop an evidence-based protocol for long-term follow-up.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

• age ≥ 18 years;

  • hydronephrosis caused by DE-related ureteral stenosis;
  • for Group F: a history of surgical treatment of ureteral endometriosis (ureterolysis, ureteroureterostomy, UCNA) at our center at least 24 months previously;
  • for Group S: indication for surgical treatment because of hydronephrosis or clinically significant ureteral stenosis;
  • signed informed consent.

Exclusion criteria

• pregnancy;

  • malignancy;
  • congenital uropathy;
  • other renal diseases;
  • inability to undergo dynamic renal scintigraphy (e.g., allergy to the radiopharmaceutical or severe comorbidities precluding the examination);
  • previous urinary tract surgery unrelated to ureteral endometriosis that could substantially confound the assessment of renal function.

Treatment and study plan

Primary outcomes

  1. The project will comprise two complementary components: Group F (long-term follow-up of patients at least 2 years after surgery) and Group S (the pilot component of the project - patients assessed before surgery).

    Time frame: 3 years

    Group F: To assess the long-term consequences of renal involvement in patients who underwent surgery for hydronephrosis caused by ureteral stenosis associated with deep endometriosis, including the impact on the renal parenchyma and the incidence of arterial hypertension compared with a control group of women of reproductive age without DE involvement. The effect of the type of surgical procedure (ureterolysis, ureteroneocystostomy - UCNA, ureteroureterostomy) on long-term outcomes will also be evaluated, including the risk of recurrent involvement and the need for potential reintervention.

    Control group: Women of reproductive age with no history of hydronephrosis, other renal disease, or endometriosis will be recruited from among patients evaluated for other benign conditions. As part of the study, they will undergo renal ultrasonography with assessment of renal morphology (parenchyma and Doppler perfusion characteristics), and the presence of arterial hypertension will be evaluated.

  2. Hydronephrosis Grade Assessed by Renal Ultrasound

    Time frame: At study assessment, at least 2 years after surgery.

    Hydronephrosis will be assessed by renal ultrasonography and classified as Grade 0, I, II, III, or IV. The distribution of hydronephrosis grades will be compared between the study group and the control group.

  3. Intrarenal Arterial Peak Systolic Velocity Measured by Pulsed-Wave Doppler Ultrasound

    Time frame: At study assessment, at least 2 years after surgery.

    Peak systolic velocity will be measured in intrarenal arteries using pulsed-wave Doppler ultrasonography and reported in centimetres per second.

  4. Intrarenal Arterial End-Diastolic Velocity Measured by Pulsed-Wave Doppler Ultrasound

    Time frame: At study assessment, at least 2 years after surgery.

    End-diastolic velocity will be measured in intrarenal arteries using pulsed-wave Doppler ultrasonography and reported in centimetres per second.

  5. Intrarenal Arterial Resistive Index Measured by Pulsed-Wave Doppler Ultrasound

    Time frame: At study assessment, at least 2 years after surgery.

    The intrarenal arterial resistive index will be calculated from pulsed-wave Doppler measurements using peak systolic velocity and end-diastolic velocity. Resistive index values will be compared between the study group and the control group.

Secondary outcomes

  1. Persistent Ureteral Dilatation Assessed by Ultrasound

    Time frame: At study assessment, at least 2 years after surgery.

    Ureteral dilatation will be assessed by ultrasonography and classified as transient or persistent. The number and proportion of participants with persistent ureteral dilatation will be reported.

  2. Prevalence of Arterial Hypertension

    Time frame: At study assessment, at least 2 years after surgery.

    The number and proportion of participants with arterial hypertension will be assessed and compared between patients after surgery for hydronephrosis associated with ureteral deep endometriosis and women in the control group.

  3. Recurrence of Upper Urinary Tract Involvement After Surgery

    Time frame: From surgery to long-term study assessment, at least 2 years after surgery. Secondary Outcome Measure 4

    The number and proportion of participants with recurrent ureteral dilatation or hydronephrosis after surgery for ureteral involvement associated with deep endometriosis will be recorded.

  4. Need for Reintervention for Recurrent Ureteral Involvement

    Time frame: From surgery to long-term study assessment, at least 2 years after surgery.

    The number and proportion of participants requiring additional surgical or urological intervention because of recurrent ureteral obstruction or hydronephrosis will be recorded.

Study contacts

Contact information is provided by the study sponsor or research team.

Kristýna HLinecká, MD PhD

CONTACT

[email protected]

+420605413210

Sponsors and collaborators

Lead sponsor

Charles University, Czech Republic

Other

Registry information

Acronym: RENDO

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Aug 20, 2026
Registry last updated
Aug 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.